Resources

Collaborative Project to Develop Next-Generation Cell Platform for Viral Vector Production Receives £1.1 Million Grant from Innovate UK & NRC

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today hosted a celebration for the opening of its microbial fermentation manufacturing facility in Billingham.

Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies

Cryoport Systems' new global Supply chain hub in Stevenage will enhance the company's ability to provide comprehensive supply chain and logistics solutions for advanced therapy manufacturers in the UK and across Europe.

RoslinCT is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.

This report summarises the summit’s main discussion points and takeaways and uses them as a foundation to build a strengths, weaknesses, opportunities and threats (SWOT) analysis for biomanufacturing in Europe.

Touchlight Genetics, in partnership with the National Physical Laboratory (NPL) have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call. 

Meet Ian Fotheringham, the Managing Director of Ingenza, a global CRDMO that aims to accelerate clients' journeys from discovery to clinical trials while minimising costs and risks. Their innovative codABLE® algorithm brings predictability to DNA sequence configuration, revolutionizing recombinant production of pharmaceutical and industrial molecules. Join us as we explore Ian's insights and Ingenza's ambitious goals for the future.

Scottish CRDMO Ingenza has secured innovation funding to adapt its codABLE® machine learning platform to precisely control recombinant protein expression in the industrial yeast Pichia pastoris. This game-changing project will accelerate the development of therapeutics, enzymes and other proteins by harnessing machine learning to fine-tune codon usage, ensuring seamless compatibility with the production host and maximising production yields.

In case you missed it last week, post-Brexit border paperwork and inspections have been postponed for the life sciences sector, thanks to BIA work. Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

Rinri Therapeutics is well-positioned to succeed in developing a therapy for hearing loss,  as they are now at the forefront of this rapidly evolving field and have established a strong  track record of innovation combined with preclinical and clinical progress.

In the HSC gene therapy approach pioneered by Orchard Therapeutics, working copies  of the faulty gene causing the disease is inserted and integrated into the genome of the  patients’ own HSCs.